pmid
stringlengths 8
12
| sentence
stringlengths 59
1.08k
| cancer_type
stringclasses 3
values | gene
dict | cancer
dict | CGE
stringclasses 2
values | CCS
stringclasses 3
values | PT
stringclasses 3
values | IGE
stringclasses 4
values | expression_change_keyword_1
dict | expression_change_keyword_2
dict |
|---|---|---|---|---|---|---|---|---|---|---|
21789713.s7 | Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing RLN2 levels in patients with benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p = 0.002). | prostate | {
"name": "RLN2",
"pos": [
242,
245
]
} | {
"name": "prostatic intraepithelial neoplasia",
"pos": [
181,
215
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "upregulated",
"pos": [
264,
274
],
"type": "Positive_regulation"
} |
9116750.s6 | In surgically excised adult human prostate tissues, localized accumulations of TGF-beta1 are associated with prostate cancer and benign prostatic hyperplasia (BPH). | prostate | {
"name": "TGF-beta1",
"pos": [
79,
87
]
} | {
"name": "benign prostatic hyperplasia",
"pos": [
129,
156
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "accumulations",
"pos": [
62,
74
],
"type": "Positive_regulation"
} |
14749128.s2 | In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression. | prostate | {
"name": "HIF-1alpha",
"pos": [
140,
149
]
} | {
"name": "prostate cancer",
"pos": [
9,
23
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
126,
135
],
"type": "Negative_regulation"
} |
||
14749128.s2 | In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression. | prostate | {
"name": "ILK",
"pos": [
45,
47
]
} | {
"name": "prostate cancer",
"pos": [
9,
23
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
49,
58
],
"type": "Gene_expression"
} | {
"name": "knockdown",
"pos": [
32,
40
],
"type": "Negative_regulation"
} |
||
14749128.s2 | In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression. | prostate | {
"name": "HIF-1alpha",
"pos": [
140,
149
]
} | {
"name": "prostate cancer",
"pos": [
9,
23
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
160,
169
],
"type": "Gene_expression"
} | {
"name": "inhibition",
"pos": [
126,
135
],
"type": "Negative_regulation"
} |
||
14749128.s2 | In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression. | prostate | {
"name": "VEGF",
"pos": [
155,
158
]
} | {
"name": "prostate cancer",
"pos": [
9,
23
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
126,
135
],
"type": "Negative_regulation"
} |
||
14749128.s2 | In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression. | prostate | {
"name": "VEGF",
"pos": [
155,
158
]
} | {
"name": "prostate cancer",
"pos": [
9,
23
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
160,
169
],
"type": "Gene_expression"
} | {
"name": "inhibition",
"pos": [
126,
135
],
"type": "Negative_regulation"
} |
||
14749128.s2 | In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression. | prostate | {
"name": "ILK",
"pos": [
89,
91
]
} | {
"name": "prostate cancer",
"pos": [
9,
23
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
75,
84
],
"type": "Negative_regulation"
} |
||
14749128.s4 | Inhibition of ILK activity also inhibits prostate tumor angiogenesis and suppresses tumor growth. | prostate | {
"name": "ILK",
"pos": [
14,
16
]
} | {
"name": "prostate tumor",
"pos": [
41,
54
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Inhibition",
"pos": [
0,
9
],
"type": "Negative_regulation"
} |
21125667.s0 | GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. | prostate | {
"name": "GRP78",
"pos": [
0,
4
]
} | {
"name": "prostate cancer",
"pos": [
116,
130
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulation",
"pos": [
6,
18
],
"type": "Positive_regulation"
} |
21125667.s10 | In keeping with our clinical data, activation of AR by dihydrotestosterone (DHT) potently activated GRP78 expression in both LNCaP and LNCaP-CR cells. | prostate | {
"name": "GRP78",
"pos": [
100,
104
]
} | {
"name": "LNCaP",
"pos": [
125,
129
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
106,
115
],
"type": "Gene_expression"
} | {
"name": "activated",
"pos": [
90,
98
],
"type": "Positive_regulation"
} |
||
21125667.s10 | In keeping with our clinical data, activation of AR by dihydrotestosterone (DHT) potently activated GRP78 expression in both LNCaP and LNCaP-CR cells. | prostate | {
"name": "AR",
"pos": [
49,
50
]
} | {
"name": "LNCaP",
"pos": [
125,
129
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
35,
44
],
"type": "Positive_regulation"
} |
||
21125667.s14 | Up-regulated expression of AR and GRP78 expression in untreated prostate cancer predicts a less favourable outcome. | prostate | {
"name": "AR",
"pos": [
27,
28
]
} | {
"name": "prostate cancer",
"pos": [
64,
78
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
13,
22
],
"type": "Gene_expression"
} | {
"name": "Up-regulated",
"pos": [
0,
11
],
"type": "Positive_regulation"
} |
15336984.s0 | TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression. | prostate | {
"name": "TRPV6",
"pos": [
87,
91
]
} | {
"name": "prostate cancer",
"pos": [
10,
24
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "expression",
"pos": [
106,
115
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
77,
85
],
"type": "Positive_regulation"
} |
21415100.s5 | In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of DU145 cells with decreased function of store-operated Ca(2+) entry and reduced expression of Orai1 at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2. | prostate | {
"name": "Orai1",
"pos": [
232,
236
]
} | {
"name": "DU145",
"pos": [
139,
143
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
218,
227
],
"type": "Gene_expression"
} | {
"name": "reduced",
"pos": [
210,
216
],
"type": "Negative_regulation"
} |
19789311.s6 | TSPO expression is increased in prostatic intraepithelial neoplasia, primary prostate cancer, and metastases compared with normal prostate tissue and benign prostatic hyperplasia. | prostate | {
"name": "TSPO",
"pos": [
0,
3
]
} | {
"name": "prostatic intraepithelial neoplasia",
"pos": [
32,
66
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
5,
14
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
19,
27
],
"type": "Positive_regulation"
} |
19789311.s10 | These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics. | prostate | {
"name": "TSPO",
"pos": [
33,
36
]
} | {
"name": "prostate cancer",
"pos": [
121,
135
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "blocking",
"pos": [
24,
31
],
"type": "Negative_regulation"
} |
14624913.s1 | To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE). | prostate | {
"name": "PSA",
"pos": [
266,
268
]
} | {
"name": "prostate cancer",
"pos": [
110,
124
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
230,
237
],
"type": "Positive_regulation"
} |
||
21263452.s0 | Increased levels of plasma haemoxygenase-1 in prostate cancer. | prostate | {
"name": "plasma haemoxygenase-1",
"pos": [
20,
41
]
} | {
"name": "prostate cancer",
"pos": [
46,
60
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "levels",
"pos": [
10,
15
],
"type": "Gene_expression"
} | {
"name": "Increased",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
19212833.s2 | PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells. | prostate | {
"name": "PDLIM4 mRNA",
"pos": [
0,
10
]
} | {
"name": "prostate cancer",
"pos": [
94,
108
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "protein-expression",
"pos": [
16,
33
],
"type": "Gene_expression"
} | {
"name": "reduced",
"pos": [
47,
53
],
"type": "Negative_regulation"
} |
19212833.s2 | PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells. | prostate | {
"name": "PDLIM4 mRNA",
"pos": [
0,
10
]
} | {
"name": "prostate cancer",
"pos": [
94,
108
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "reduced",
"pos": [
47,
53
],
"type": "Negative_regulation"
} |
16299799.s0 | Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. | prostate | {
"name": "PIM-1",
"pos": [
18,
22
]
} | {
"name": "prostate carcinoma",
"pos": [
52,
69
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "Overexpression",
"pos": [
0,
13
],
"type": "Gene_expression"
} | {
"name": "Overexpression",
"pos": [
0,
13
],
"type": "Positive_regulation"
} |
18281549.s0 | Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. | prostate | {
"name": "Bcl-XL",
"pos": [
123,
128
]
} | {
"name": "prostate cancer",
"pos": [
65,
79
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulates",
"pos": [
85,
98
],
"type": "Negative_regulation"
} |
||
18281549.s0 | Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. | prostate | {
"name": "survivin",
"pos": [
134,
141
]
} | {
"name": "prostate cancer",
"pos": [
65,
79
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulates",
"pos": [
85,
98
],
"type": "Negative_regulation"
} |
||
20873592.s5 | Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05). | prostate | {
"name": "miR-182",
"pos": [
132,
138
]
} | {
"name": "BPH",
"pos": [
14,
16
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expressions",
"pos": [
109,
119
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
99,
107
],
"type": "Negative_regulation"
} |
20873592.s5 | Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05). | prostate | {
"name": "miR-183",
"pos": [
144,
150
]
} | {
"name": "BPH",
"pos": [
14,
16
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expressions",
"pos": [
109,
119
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
99,
107
],
"type": "Negative_regulation"
} |
20873592.s5 | Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05). | prostate | {
"name": "miR-98",
"pos": [
68,
73
]
} | {
"name": "BPH",
"pos": [
14,
16
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expressions",
"pos": [
53,
63
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
43,
51
],
"type": "Negative_regulation"
} |
20873592.s5 | Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P < 0.05). | prostate | {
"name": "miR-96",
"pos": [
124,
129
]
} | {
"name": "BPH",
"pos": [
14,
16
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expressions",
"pos": [
109,
119
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
99,
107
],
"type": "Negative_regulation"
} |
16763719.s4 | With the treatment of 9-cis RA, the NKX3.1 promoter activity was increased in reporter gene assay and NKX3.1 expression was enhanced at both mRNA and protein levels in LNCaP cells. | prostate | {
"name": "NKX3.1",
"pos": [
102,
107
]
} | {
"name": "LNCaP",
"pos": [
168,
172
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
109,
118
],
"type": "Gene_expression"
} | {
"name": "enhanced",
"pos": [
124,
131
],
"type": "Positive_regulation"
} |
||
16763719.s4 | With the treatment of 9-cis RA, the NKX3.1 promoter activity was increased in reporter gene assay and NKX3.1 expression was enhanced at both mRNA and protein levels in LNCaP cells. | prostate | {
"name": "NKX3.1 promoter",
"pos": [
36,
50
]
} | {
"name": "LNCaP",
"pos": [
168,
172
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
65,
73
],
"type": "Positive_regulation"
} |
||
16763719.s7 | Our results demonstrated that 9-cis RA as a differentiating agent can arrest prostate cancer cells in G(1) phase and reduce cell mitosis, and upregulate the expression of human homeobox gene NKX3.1, which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate. | prostate | {
"name": "human homeobox gene NKX3.1",
"pos": [
171,
196
]
} | {
"name": "prostate cancer",
"pos": [
77,
91
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "expression",
"pos": [
157,
166
],
"type": "Gene_expression"
} | {
"name": "upregulate",
"pos": [
142,
151
],
"type": "Positive_regulation"
} |
1458483.s9 | Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence. | prostate | {
"name": "bcl-2",
"pos": [
27,
31
]
} | {
"name": "prostate cancer",
"pos": [
127,
141
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
33,
42
],
"type": "Gene_expression"
} | {
"name": "augmented",
"pos": [
47,
55
],
"type": "Positive_regulation"
} |
15647830.s0 | A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer. | prostate | {
"name": "ubiquitin carboxyl extension protein 1",
"pos": [
44,
81
]
} | {
"name": "prostate cancer",
"pos": [
103,
117
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
86,
98
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
86,
98
],
"type": "Positive_regulation"
} |
15647830.s7 | Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper. | prostate | {
"name": "UBCEP-1",
"pos": [
89,
95
]
} | {
"name": "prostate carcinoma",
"pos": [
106,
123
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulation",
"pos": [
32,
44
],
"type": "Positive_regulation"
} |
15647830.s7 | Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper. | prostate | {
"name": "ubiquitin carboxyl extension protein 1",
"pos": [
49,
86
]
} | {
"name": "prostate carcinoma",
"pos": [
106,
123
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulation",
"pos": [
32,
44
],
"type": "Positive_regulation"
} |
15657352.s0 | Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells. | prostate | {
"name": "c-Jun-NH2-kinase",
"pos": [
17,
32
]
} | {
"name": "prostate cancer",
"pos": [
145,
159
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Up-regulation",
"pos": [
0,
12
],
"type": "Positive_regulation"
} |
8780381.s0 | Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. | prostate | {
"name": "beta 1C integrin",
"pos": [
19,
34
]
} | {
"name": "prostate carcinoma",
"pos": [
76,
93
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Down-regulation",
"pos": [
0,
14
],
"type": "Negative_regulation"
} |
8780381.s4 | In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged. | prostate | {
"name": "beta 1C variant",
"pos": [
52,
66
]
} | {
"name": "prostate adenocarcinoma",
"pos": [
16,
38
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulated",
"pos": [
85,
98
],
"type": "Negative_regulation"
} |
15017584.s6 | Our findings indicate a significant reduction in p27Kip1 immunoreactivity in HGPIN (P<0.0001) and prostate cancer (P<0.0001) compared with the benign tissue. | prostate | {
"name": "p27Kip1",
"pos": [
49,
55
]
} | {
"name": "prostate cancer",
"pos": [
101,
115
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "reduction",
"pos": [
36,
44
],
"type": "Negative_regulation"
} |
17363494.s5 | Resveratrol- and EGCG-induced apoptosis is associated with a significant down-regulation of CK2 activity and protein expression in both the ALVA-41 and PC-3 cells. | prostate | {
"name": "CK2",
"pos": [
92,
94
]
} | {
"name": "ALVA-41",
"pos": [
140,
146
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulation",
"pos": [
73,
87
],
"type": "Negative_regulation"
} |
17363494.s5 | Resveratrol- and EGCG-induced apoptosis is associated with a significant down-regulation of CK2 activity and protein expression in both the ALVA-41 and PC-3 cells. | prostate | {
"name": "CK2",
"pos": [
92,
94
]
} | {
"name": "ALVA-41",
"pos": [
140,
146
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
117,
126
],
"type": "Gene_expression"
} | {
"name": "down-regulation",
"pos": [
73,
87
],
"type": "Negative_regulation"
} |
17363494.s6 | Overexpression of CK2alpha protected prostatic cancer cells against resveratrol- and EGCG-induced apoptosis. | prostate | {
"name": "CK2alpha",
"pos": [
18,
25
]
} | {
"name": "prostatic cancer",
"pos": [
37,
52
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "Overexpression",
"pos": [
0,
13
],
"type": "Gene_expression"
} | {
"name": "Overexpression",
"pos": [
0,
13
],
"type": "Positive_regulation"
} |
12808114.s8 | The frequencies of loss for areas known to be frequently deleted in prostate cancer, such as 6q, 8p, or 13q, were not different between the two groups. | prostate | {
"name": "6q",
"pos": [
93,
94
]
} | {
"name": "prostate cancer",
"pos": [
68,
82
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "deleted",
"pos": [
57,
63
],
"type": "Negative_regulation"
} |
||
11069386.s7 | The study suggests that IGF-II has a role in regulating AR expression in prostate cancer cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression. | prostate | {
"name": "IGF-II",
"pos": [
179,
184
]
} | {
"name": "prostate cancer",
"pos": [
73,
87
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
186,
195
],
"type": "Gene_expression"
} | {
"name": "suppress",
"pos": [
170,
177
],
"type": "Negative_regulation"
} |
||
18332867.s3 | Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. | prostate | {
"name": "PSA",
"pos": [
86,
88
]
} | {
"name": "PWR-1E",
"pos": [
183,
188
]
} | decreased | unidentifiable | {
"name": "levels",
"pos": [
91,
96
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
38,
46
],
"type": "Negative_regulation"
} |
||
18332867.s3 | Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. | prostate | {
"name": "prostate specific antigen",
"pos": [
59,
83
]
} | {
"name": "PWR-1E",
"pos": [
183,
188
]
} | decreased | unidentifiable | {
"name": "levels",
"pos": [
91,
96
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
38,
46
],
"type": "Negative_regulation"
} |
||
18332867.s3 | Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. | prostate | {
"name": "AR",
"pos": [
52,
53
]
} | {
"name": "PWR-1E",
"pos": [
183,
188
]
} | decreased | unidentifiable | {
"name": "levels",
"pos": [
91,
96
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
38,
46
],
"type": "Negative_regulation"
} |
||
17203235.s0 | Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. | prostate | {
"name": "BMPR-IB",
"pos": [
104,
110
]
} | {
"name": "prostate cancer",
"pos": [
134,
148
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
42,
51
],
"type": "Gene_expression"
} | {
"name": "up-regulates",
"pos": [
25,
36
],
"type": "Positive_regulation"
} |
||
17203235.s0 | Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. | prostate | {
"name": "bone morphogenetic protein (BMP) receptors",
"pos": [
60,
101
]
} | {
"name": "prostate cancer",
"pos": [
134,
148
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
42,
51
],
"type": "Gene_expression"
} | {
"name": "up-regulates",
"pos": [
25,
36
],
"type": "Positive_regulation"
} |
||
17203235.s0 | Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. | prostate | {
"name": "BMPR-II",
"pos": [
116,
122
]
} | {
"name": "prostate cancer",
"pos": [
134,
148
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
42,
51
],
"type": "Gene_expression"
} | {
"name": "up-regulates",
"pos": [
25,
36
],
"type": "Positive_regulation"
} |
||
17203235.s12 | In a murine prostate tumour model, infusion of recombinant HGF resulted in an increase in the levels of both BMPR-IB and BMPR-II transcript in prostate tumours. | prostate | {
"name": "BMPR-II transcript",
"pos": [
121,
138
]
} | {
"name": "prostate tumours",
"pos": [
143,
158
]
} | increased | unidentifiable | {
"name": "levels",
"pos": [
94,
99
],
"type": "Gene_expression"
} | {
"name": "increase",
"pos": [
78,
85
],
"type": "Positive_regulation"
} |
||
17203235.s12 | In a murine prostate tumour model, infusion of recombinant HGF resulted in an increase in the levels of both BMPR-IB and BMPR-II transcript in prostate tumours. | prostate | {
"name": "BMPR-IB",
"pos": [
109,
115
]
} | {
"name": "prostate tumours",
"pos": [
143,
158
]
} | increased | unidentifiable | {
"name": "levels",
"pos": [
94,
99
],
"type": "Gene_expression"
} | {
"name": "increase",
"pos": [
78,
85
],
"type": "Positive_regulation"
} |
||
17203235.s14 | In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo. | prostate | {
"name": "bone morphogenetic protein receptors",
"pos": [
54,
89
]
} | {
"name": "prostate cancer",
"pos": [
116,
130
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
36,
45
],
"type": "Gene_expression"
} | {
"name": "up-regulates",
"pos": [
19,
30
],
"type": "Positive_regulation"
} |
||
17203235.s14 | In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo. | prostate | {
"name": "BMPR-II",
"pos": [
104,
110
]
} | {
"name": "prostate cancer",
"pos": [
116,
130
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
36,
45
],
"type": "Gene_expression"
} | {
"name": "up-regulates",
"pos": [
19,
30
],
"type": "Positive_regulation"
} |
||
17203235.s14 | In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo. | prostate | {
"name": "BMPR-IB",
"pos": [
92,
98
]
} | {
"name": "prostate cancer",
"pos": [
116,
130
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
36,
45
],
"type": "Gene_expression"
} | {
"name": "up-regulates",
"pos": [
19,
30
],
"type": "Positive_regulation"
} |
||
19470787.s0 | 3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. | prostate | {
"name": "p38 mitogen-activated protein kinase",
"pos": [
71,
106
]
} | {
"name": "prostate cancer",
"pos": [
119,
133
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
22,
30
],
"type": "Positive_regulation"
} |
19470787.s5 | Transfection of the PC-3 prostate cell line with a dominant-negative form of p75(NTR) before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75(NTR) levels and inhibition of survival. | prostate | {
"name": "NTR",
"pos": [
218,
220
]
} | {
"name": "PC-3",
"pos": [
20,
23
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
201,
209
],
"type": "Positive_regulation"
} |
19470787.s5 | Transfection of the PC-3 prostate cell line with a dominant-negative form of p75(NTR) before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75(NTR) levels and inhibition of survival. | prostate | {
"name": "p75",
"pos": [
214,
216
]
} | {
"name": "PC-3",
"pos": [
20,
23
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
201,
209
],
"type": "Positive_regulation"
} |
19470787.s6 | Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of p75(NTR) by DIM in the PC-3 prostate cell line. | prostate | {
"name": "p75",
"pos": [
111,
113
]
} | {
"name": "PC-3",
"pos": [
134,
137
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
98,
106
],
"type": "Positive_regulation"
} |
||
19470787.s6 | Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of p75(NTR) by DIM in the PC-3 prostate cell line. | prostate | {
"name": "NTR",
"pos": [
115,
117
]
} | {
"name": "PC-3",
"pos": [
134,
137
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
98,
106
],
"type": "Positive_regulation"
} |
||
12414626.s0 | Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. | prostate | {
"name": "mitogen-activated protein kinase",
"pos": [
14,
45
]
} | {
"name": "prostate cancer",
"pos": [
122,
136
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Activation",
"pos": [
0,
9
],
"type": "Positive_regulation"
} |
||
12414626.s4 | We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy. | prostate | {
"name": "mitogen-activated protein (MAP) kinase",
"pos": [
45,
82
]
} | {
"name": "prostate tumors",
"pos": [
87,
101
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activated",
"pos": [
35,
43
],
"type": "Positive_regulation"
} |
||
12414626.s4 | We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy. | prostate | {
"name": "mitogen-activated protein (MAP) kinase",
"pos": [
45,
82
]
} | {
"name": "prostate tumors",
"pos": [
87,
101
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
23,
30
],
"type": "Positive_regulation"
} |
||
7525636.s5 | In the CM of BPH stromal cells, IGFBP-2 levels were dramatically reduced to less than 20% of normal (P < 0.001). | prostate | {
"name": "IGFBP-2",
"pos": [
32,
38
]
} | {
"name": "BPH",
"pos": [
13,
15
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "levels",
"pos": [
40,
45
],
"type": "Gene_expression"
} | {
"name": "reduced",
"pos": [
65,
71
],
"type": "Negative_regulation"
} |
7525636.s7 | Northern blot analysis of mRNA from normal and BPH stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells. | prostate | {
"name": "IGFBP-5 mRNA",
"pos": [
152,
163
]
} | {
"name": "BPH",
"pos": [
47,
49
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
140,
147
],
"type": "Positive_regulation"
} |
7525636.s7 | Northern blot analysis of mRNA from normal and BPH stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells. | prostate | {
"name": "IGFBP-2 mRNA",
"pos": [
99,
110
]
} | {
"name": "BPH",
"pos": [
47,
49
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decrease",
"pos": [
87,
94
],
"type": "Negative_regulation"
} |
15326487.s10 | These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients. | prostate | {
"name": "SRD5A2 locus",
"pos": [
117,
128
]
} | {
"name": "prostate cancer",
"pos": [
133,
147
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
91,
99
],
"type": "Positive_regulation"
} |
17712489.s0 | Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells. | prostate | {
"name": "telomerase",
"pos": [
14,
23
]
} | {
"name": "prostate cancer",
"pos": [
157,
171
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Inhibition",
"pos": [
0,
9
],
"type": "Negative_regulation"
} |
17712489.s15 | hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells. | prostate | {
"name": "hTERT mRNA",
"pos": [
84,
93
]
} | {
"name": "PC3",
"pos": [
212,
214
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "expression",
"pos": [
107,
116
],
"type": "Gene_expression"
} | {
"name": "downregulating",
"pos": [
65,
78
],
"type": "Negative_regulation"
} |
17712489.s15 | hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells. | prostate | {
"name": "hTERT mRNA",
"pos": [
84,
93
]
} | {
"name": "PC3",
"pos": [
212,
214
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "downregulating",
"pos": [
65,
78
],
"type": "Negative_regulation"
} |
16044418.s0 | Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. | prostate | {
"name": "Akt",
"pos": [
18,
20
]
} | {
"name": "prostate cancer",
"pos": [
168,
182
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Inhibition",
"pos": [
0,
9
],
"type": "Negative_regulation"
} |
16044418.s0 | Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. | prostate | {
"name": "cyclooxygenase-2",
"pos": [
23,
38
]
} | {
"name": "prostate cancer",
"pos": [
168,
182
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Inhibition",
"pos": [
0,
9
],
"type": "Negative_regulation"
} |
16044418.s5 | Previous studies by us and others, with androgen-sensitive prostate cancer cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, COX-2, and MMP-9 in cells. | prostate | {
"name": "COX-2",
"pos": [
176,
180
]
} | {
"name": "prostate cancer",
"pos": [
59,
73
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
142,
151
],
"type": "Positive_regulation"
} |
||
21861338.s8 | R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha. | prostate | {
"name": "estrogen receptor-alpha",
"pos": [
198,
220
]
} | {
"name": "DU145",
"pos": [
71,
75
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
184,
193
],
"type": "Positive_regulation"
} |
18816901.s0 | Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. | prostate | {
"name": "p27",
"pos": [
13,
15
]
} | {
"name": "prostate cancer",
"pos": [
137,
151
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Induction",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
||
18816901.s0 | Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. | prostate | {
"name": "kip1",
"pos": [
17,
20
]
} | {
"name": "prostate cancer",
"pos": [
137,
151
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Induction",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
||
18816901.s5 | These results suggest that TMS may inhibit the cell cycle through induction of p27(kip1), leading to apoptotic cell death in PC-3 prostate cancer cells. | prostate | {
"name": "kip1",
"pos": [
83,
86
]
} | {
"name": "prostate cancer",
"pos": [
130,
144
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
66,
74
],
"type": "Positive_regulation"
} |
18816901.s5 | These results suggest that TMS may inhibit the cell cycle through induction of p27(kip1), leading to apoptotic cell death in PC-3 prostate cancer cells. | prostate | {
"name": "p27",
"pos": [
79,
81
]
} | {
"name": "prostate cancer",
"pos": [
130,
144
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
66,
74
],
"type": "Positive_regulation"
} |
14735192.s9 | Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer. | prostate | {
"name": "EGFR",
"pos": [
52,
55
]
} | {
"name": "prostate cancer",
"pos": [
98,
112
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
57,
66
],
"type": "Negative_regulation"
} |
||
22043900.s4 | We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. | prostate | {
"name": "DR3",
"pos": [
93,
95
]
} | {
"name": "PC3",
"pos": [
115,
117
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
23,
32
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
102,
110
],
"type": "Positive_regulation"
} |
22043900.s4 | We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. | prostate | {
"name": "DR3",
"pos": [
156,
158
]
} | {
"name": "PC3",
"pos": [
115,
117
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
134,
143
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
164,
172
],
"type": "Positive_regulation"
} |
||
22043900.s4 | We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. | prostate | {
"name": "tumour necrosis factor receptor 2 and death receptor 3",
"pos": [
37,
90
]
} | {
"name": "PC3",
"pos": [
115,
117
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
23,
32
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
102,
110
],
"type": "Positive_regulation"
} |
22043900.s4 | We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. | prostate | {
"name": "FAS",
"pos": [
148,
150
]
} | {
"name": "PC3",
"pos": [
115,
117
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
134,
143
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
164,
172
],
"type": "Positive_regulation"
} |
||
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "alpha 1-globulin",
"pos": [
839,
854
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | increased | unidentifiable | {
"name": "levels",
"pos": [
880,
885
],
"type": "Gene_expression"
} | {
"name": "increase",
"pos": [
827,
834
],
"type": "Positive_regulation"
} |
||
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "albumin",
"pos": [
794,
800
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decrease",
"pos": [
782,
789
],
"type": "Negative_regulation"
} |
||
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "alpha 1- and gamma-globulin",
"pos": [
567,
593
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
555,
562
],
"type": "Positive_regulation"
} |
||
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "alpha 2-globulin",
"pos": [
806,
821
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decrease",
"pos": [
782,
789
],
"type": "Negative_regulation"
} |
||
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "alpha 2- and beta-globulin",
"pos": [
289,
314
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
264,
271
],
"type": "Positive_regulation"
} |
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "alpha 1-globulin",
"pos": [
839,
854
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
827,
834
],
"type": "Positive_regulation"
} |
||
91252.s3 | Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy. | prostate | {
"name": "albumin",
"pos": [
515,
521
]
} | {
"name": "prostatic cancer",
"pos": [
177,
192
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decrease",
"pos": [
503,
510
],
"type": "Negative_regulation"
} |
||
15368472.s0 | Trefoil factor 3 is overexpressed in human prostate cancer. | prostate | {
"name": "Trefoil factor 3",
"pos": [
0,
15
]
} | {
"name": "prostate cancer",
"pos": [
43,
57
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
20,
32
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
20,
32
],
"type": "Positive_regulation"
} |
15368472.s3 | Recent cDNA array analyses suggest that human intestinal trefoil factor 3 (TFF3) may be overexpressed in human prostate cancer. | prostate | {
"name": "human intestinal trefoil factor 3",
"pos": [
40,
72
]
} | {
"name": "prostate cancer",
"pos": [
111,
125
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
88,
100
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
88,
100
],
"type": "Positive_regulation"
} |
15368472.s3 | Recent cDNA array analyses suggest that human intestinal trefoil factor 3 (TFF3) may be overexpressed in human prostate cancer. | prostate | {
"name": "TFF3",
"pos": [
75,
78
]
} | {
"name": "prostate cancer",
"pos": [
111,
125
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
88,
100
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
88,
100
],
"type": "Positive_regulation"
} |
15368472.s11 | These studies validate that TFF3 is overexpressed in a subset of primary and metastic prostate cancers. | prostate | {
"name": "TFF3",
"pos": [
28,
31
]
} | {
"name": "prostate cancers",
"pos": [
86,
101
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
36,
48
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
36,
48
],
"type": "Positive_regulation"
} |
12095941.s12 | Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells. | prostate | {
"name": "Cx32",
"pos": [
110,
113
]
} | {
"name": "RWPE-1",
"pos": [
129,
134
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
115,
124
],
"type": "Gene_expression"
} | {
"name": "reduction",
"pos": [
97,
105
],
"type": "Negative_regulation"
} |
||
12095941.s12 | Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells. | prostate | {
"name": "Cx43",
"pos": [
59,
62
]
} | {
"name": "RWPE-1",
"pos": [
129,
134
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
34,
41
],
"type": "Positive_regulation"
} |
||
12095941.s12 | Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells. | prostate | {
"name": "connexin 43",
"pos": [
46,
56
]
} | {
"name": "RWPE-1",
"pos": [
129,
134
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
34,
41
],
"type": "Positive_regulation"
} |
||
14971644.s0 | Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. | prostate | {
"name": "HIF-1alpha",
"pos": [
17,
26
]
} | {
"name": "prostate carcinoma",
"pos": [
98,
115
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induces",
"pos": [
9,
15
],
"type": "Positive_regulation"
} |
||
14971644.s0 | Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. | prostate | {
"name": "VEGF",
"pos": [
32,
35
]
} | {
"name": "prostate carcinoma",
"pos": [
98,
115
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induces",
"pos": [
9,
15
],
"type": "Positive_regulation"
} |
||
14971644.s0 | Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. | prostate | {
"name": "PI3K",
"pos": [
45,
48
]
} | {
"name": "prostate carcinoma",
"pos": [
98,
115
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induces",
"pos": [
9,
15
],
"type": "Positive_regulation"
} |